Alnylam Pharmaceuticals, Inc. (ALNY) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

19/25

Growth 5 Margin 3 Expansion 5 Platform 2 Financial 4

latest quarter score

Earnings Reports

19
Alnylam (ALNY) Q2 2026: Amvutra First-Line Penetration Drives 74% TTR Revenue Growth Amid Guidance Reset
July 30, 2026
21
Alnylam (ALNY) Q4 2025: TTR Franchise Soars 151%, Anchoring 2030 Growth Ambitions
June 16, 2026
21
Alnylam (ALNY) Q1 2026: TTR Franchise Surges 153% YoY, Propelling $1B+ Quarterly Milestone
April 30, 2026
18
Alnylam (ALNY) Q3 2025: TTR Franchise Soars 135% as Amvuttra Cardiomyopathy Launch Doubles U.S. Demand
October 30, 2025
19
Alnylam (ALNY) Q2 2025: TTR Franchise Surges 77% on Ambutra Launch, Guidance Raised $575M
July 31, 2025
21
Alnylam (ALNY) Q1 2025: TTR Franchise Soars 36% as ATTR-CM Launch Accelerates Access
July 04, 2025
Alnylam (ALNY) Q3 2024: TTR Franchise Climbs 34% as ATTR-CM Launch Preparation Accelerates
October 31, 2024
Alnylam (ALNY) Q2 2024: TTR Franchise Grows 37%, Helios B Data Sets Up Cardiomyopathy Launch
August 01, 2024
Alnylam (ALNY) Q1 2024: TTR Franchise Up 29% as Helios B Readout Nears Pivotal Moment
May 02, 2024
Alnylam (ALNY) Q4 2023: TTR Franchise Surges 33% as Helios-B Study Extension Targets Competitive Label
February 15, 2024
17
Alnylam (ALNY) Q3 2023: Collaboration Revenue Surges $400M as ATTR Franchise Expands
November 02, 2023
Alnylam (ALNY) Q2 2023: TTR Franchise Grows 46% as Pipeline and Roche Partnership Expand Future Optionality
August 03, 2023
Alnylam (ALNY) Q1 2023: TTR Franchise Surges 75% in U.S., CNS RNAi Data Opens New Pipeline Horizons
May 04, 2023
Alnylam (ALNY) Q4 2022: Ambutra Launch Drives 38% TTR Franchise Growth, Pipeline Milestones Set Stage for 2023
February 23, 2023

Browse all companies